Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.55 |
| ▸ | CDC42BPA | Q5VT25 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12602453 | 0.91 | ROCK2 (0.46) | ROCK2ROCK1CDC42BPA | |
| SCHEMBL1986956 | 0.89 | ROCK2 (0.60) | ROCK2ROCK1CDC42BPALMNATP53 | |
| SCHEMBL1987269 | 0.89 | ROCK2 (0.69) | ROCK2ROCK1CDC42BPA | |
| SCHEMBL1988309 | 0.89 | ROCK2 (0.60) | ROCK2ROCK1CDC42BPALMNATP53 | |
| SCHEMBL12562361 | 0.87 | ROCK2 (0.62) | ROCK2ROCK1CDC42BPA | |
| SCHEMBL12562050 | 0.85 | ROCK2 (0.77) | ROCK2ROCK1CDC42BPA | |
| SCHEMBL12562399 | 0.85 | ROCK2 (0.59) | ROCK2ROCK1CDC42BPALMNATP53 | |
| SCHEMBL1986321 | 0.84 | ROCK2 (0.64) | ROCK2ROCK1CDC42BPA | |
| SCHEMBL1989750 | 0.83 | ROCK2 (0.79) | ROCK2ROCK1CDC42BPA | |
| SCHEMBL12562386 | 0.83 | ROCK2 (0.59) | ROCK2ROCK1CDC42BPALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2009079008-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | FENG YANGBO (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150833-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | ROCK1, RHOA, RHOT2 | ROCK2 4/4885ROCK1 1/4885CDC42BPA 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.